netFormulary
Data extracted : 24/11/2017
 Formulary Section 5: Infections
 Details...
05.01 Antibacterial drugs

  • For full prescribing information, please see antimicrobial website

  • For information regarding restricted antibiotics, please see restricted antibiotics page within antibiotic guide
Link   NHSE commissioning policy: Inhaled Therapy for Adults and Children With Cystic Fibrosis
Link   Restricted antibiotics
Second Choice:
Nitrofurantoin 
  • Second line choice, reserved for patients resistant to trimethoprim in uncomplicated UTI
  • Capsules are the preferred option
  • Tablets are reserved for enteral tube administration
  • Nitrofurantoin 25mg/5ml suspension significantly more expensive. Please refer to pharmacy for more information
  • Restricted Drug  Aztreonam  (Cayston)
    For nebulisation in Cystic Fibrosis.
    NHSE commissioned
    Restricted Drug  Colistimethate sodium 
    Colomycin powder for reconstitution for nebulisation. Promixin powder for nebuliser solution.
    Please ensure colistimethate is prescribed and dispensed by brand. Due to the devises they are used with, they may not be interchangeable.

    Used in bronchiectasis and cystic fibrosis. Latter is high cost drug excluded to tariff, NHSE commissioned.
    Specialist Respiratory prescribing
    See Antimicrobial website for further details
    Restricted Drug  Colistimethate sodium   (Colobreathe)
    Dry powder for inhalation, hard capsule
    For use in cystic fibrosis in line with NICE TA 276 only.
    High cost drug excluded to tariff, NHSE commissioned.
    Specialist Respiratory prescribing.

    Date of entry of decision to Formulary: April 2013
    Restricted Drug  Rifaximin  
    Specialist hepatologist initiation only for hepatic encephalopathy

    Date decision added to Formulary: June 15
    Restricted Drug  Sodium fusidate  (Fusidic acid)
    Oral and Intravenous
    See antimicrobial website.
    Restricted antibiotic, microbiology approval needed
    Restricted Drug  Tobramycin   (Bramitob)
    Nebuliser solution for inhalation in cystic fibrosis
    High cost drug excluded to tariff, NHSE commissioned.
    Specialist Respiratory prescribing
    See Antimicrobial Website for further information.
    Restricted Drug  Tobramycin   (Tobi podhaler )
    Dry powder for inhalation
    For use in cystic fibrosis in line with NICE TA 276 only.
    High cost drug excluded to tariff, NHSE commissioned.
    Specialist Respiratory prescribing

    Date of entry of decision to Formulary: April 2013
    05.02.01 Triazole antifungals

    Posaconazole and Voriconazole are high cost drugs excluded to tariff, NHSE commissioned.  See Antimicrobial website for further details

    Link   MHRA Advice: Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable
    05.02.03 Polyene antifungals
    Amphotericin liposomal formulations are high cost drugs excluded to tariff, commissioned by NHSE.  See Antimicrobial Website for further details.
    05.02.04 Echinocandin antifungals
    Caspofungin and Micafungin are high cost drugs excluded to tariff commissioned by NHSE.  See antimicrobial website for further information
    05.03 Antiviral drugs
    05.03.01 HIV infection
    Link   British HIVA Association guidelines: Treatment of HIV-1-positive adults with antiretroviral therapy
    Link   MHRA Advice: Antiretroviral medicines: updated advice on body-fat changes and lactic acidosis
    05.03.01 Nucleoside reverse transcriptase inhibitors
    Restricted Drug  Abacavir 
    Restricted Drug  Abacavir and Lamivudine  (Kivexa)
    High Cost Therapy excluded to tariff
    Restricted Drug  Didanosine 
    High Cost Therapy excluded to tariff
    Restricted Drug  Efavirenz, Emtricitabine and Tenofovir Disoproxil  (Atripla)
    High Cost Therapy excluded to tariff
    Restricted Drug  Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide   (Genvoya)
    High Cost Therapy excluded to tariff
    Restricted Drug  Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Disoproxil   (Stribild)
    Restricted Drug  Emtricitabine 
    High Cost Therapy excluded to tariff
    Restricted Drug  Emtricitabine and Tenofovir Alafenamide  (Descovy)
    High cost drug excluded to tariff
    Restricted, to be used in line with NHSE policy only
    Restricted Drug  Emtricitabine, Rilpivirine and Tenofovir Alafenamide  (Odefsey)
    High cost therapy excluded to tarrif
    Restricted, to be used in line with NHSE policy only
    Restricted Drug  Emtricitabine, Rilpivirine and Tenofovir Disoproxil   (Eviplera)
    High Cost Therapy excluded to tariff
    Only for those intolerant or non responsive to Atripla
    Restricted Drug  Lamivudine 
    High Cost Therapy excluded to tariff
    Also used in treatment of Hepatitis B, commissioned by NHSE in line with NICE CG165 only
    Restricted Drug  Tenofovir Disoproxil 
    High Cost Therapy excluded to tariff
    Restricted Drug  Tenofovir Disoproxil and Emtricitabine  (Truvada)
    High Cost Drug excluded to tariff
    Restricted Drug  Zidovudine 
    High Cost Therapy excluded to tariff
    Restricted Drug  Zidovudine and Lamivudine 
    High Cost Therapy excluded to tariff
    Generic combination has a lower cost than the individual components prescribed separately
    05.03.01 Protease inhibitors
    Restricted Drug  Atazanavir 
    High Cost Therapy excluded to tariff
    Restricted Drug  Atazanavir with Cobicistat  (Evotaz)
    High Cost Therapy excluded to tariff
    Restricted Drug  Darunavir with Cobicistat  (Rezolsta )
    High Cost Therapy excluded to tariff
    Restricted Drug  Fosamprenavir 
    High Cost Drug excluded to tariff
    Restricted Drug  Lopinavir with Ritonavir  (Kaletra)
    High Cost Drug excluded to tariff
    Restricted Drug  Ritonavir 
    High Cost Therapy excluded to tariff
    Restricted Drug  Tipranavir 
    High Cost Therapy excluded to tariff
    Third line therapy
    Restricted Drug  Darunavir 
    High Cost Therapy excluded to tariff
    2nd line Protease Inhibitor (PI) in patients who have failed at least one PI containing regimen. Recommended to be used in preference to tipranavir where both are an option.
    05.03.01 Other antiretrovirals
    Restricted Drug  Enfuvirtide 
    High Cost Drug excluded to tariff
    Restricted Drug  Raltegravir 
    High Cost Therapy excluded to tariff
    Restricted Drug  Cobicistat  
    Pharmacoenhancer

    High Cost Therapy excluded to tariff
    For use in line with NHSE policy only
    Restricted Drug  Dolutegravir 
    High Cost Therapy excluded to tariff
    Supported in line with NHSE policy only.

    Restricted Drug  Dolutegravir, Abacavir and Lamivudine  (Triumeq)
    High Cost Therapy excluded to tariff
    Supported in line with NHSE policy only.

    Restricted Drug  Maraviroc 
    High Cost Therapy excluded to tariff
    For use in treatment experienced adult patients infected with only CCR5-tropic HIV-1 virus.
    05.03.02.02 Cytomegalovirus infrection
    Cidofovir, Foscarnet, Ganciclovir and Valganciclovir are high cost drugs excluded to tariff commissioned by NHSE in line with Trust guidelines for Cytomegalovirus infection.
    05.03.03 Viral hepatitis
    Restricted Drug  Daclatasvir  
    Specialist prescribing in Hepatitis C
    Commissioned by NHSE in line with NICE TA only
    Blueteq prior approval required before initiation



    Date of entry of decision to formulary: February 2016
    Restricted Drug  Dasabuvir  
    Specialist use in Hepatitis C
    NHSE commissioned in line with NICE TA 365
    Blueteq prior approval required before intiation

    Date of entry of decision to Formulary: March 2016
    Restricted Drug  Elbasvir and grazoprevir  (Zepatier)
    Specialist use in Hepatitis C
    NHSE commissioned in line with NICE TA 413
    Blueteq prior approval required before initiation

    Date of entry of decision to formulary: January 2017
    Restricted Drug  Entecavir  
    Specialist prescribing in Hepatitis B
    Commissioned by NHSE in line with NICE TA 153 only
    Restricted Drug  Ledipasvir and sofosbuvir   (Harvoni)
    Specialist prescribing in Hepatitis C
    Commissioned by NHSE in line with NICE TA only
    Blueteq prior approval required before initiation

    Date of entry of decision to formulary: February 2016
    Restricted Drug  Ombitasvir, paritaprevir, and ritonavir   (Viekirax)
    Specialist prescribing in Hepatitis C
    NHSE commissioned in line with NICE TA only with or without Dasabuvir
    Blueteq prior approval required before initiation


    Date of entry of decision to formulary: February 2016
    Restricted Drug  Simeprevir 
    Specialist prescribing in Hepatitis C
    Commissioned by NHSE in line with NICE TA only.

    Genotype 4 patients require Blueteq prior approval before initiation

    Date decision added to Formulary: May 15
    Restricted Drug  Sofosbuvir 
    Specialist prescribing in Hepatitis C
    NHSE commissioned in line with NICE TA only
    Blueteq prior approval required before initiation

    Date decision added to Formulary: May 15
    Restricted Drug  Sofosbuvir/valpatasvir  (Epclusa)
    Specialist prescribing in Hepatitis C
    NHSE commissioned in line with NICE TA only
    Blueteq prior approval required before initiation

    Date decision added to Formulary: March 17
    Restricted Drug  Boceprevir 
    Specialist prescribing in Hepatitis C
    Commissioned by NHSE in line with NICE TA 253 only

    Date of entry of decision to Formulary: May 2012

    Use superceded by newer drugs for Hepatitis C
    Restricted Drug  Telaprevir 
    Specialist prescribing in Hepatitis C
    High cost drug excluded to tariff. Commissioned by NHSE in line with NICE TA 252 only

    Date of entry of decision to Formulary: May 2012

    Use superceded by newer drugs for Hepatitis C
    05.03.05 Respiratory syncytial virus
    Restricted Drug  Palivizumab  (Synagis)
    Respiratory syncytial virus (RSV) prophylaxis
    High cost drug excluded to tariff commissioned by NHSE

    Supported in line with JVCI guidance

    From 16/17 season Blueteq prior approval required before initiation

    Restricted Drug  Ribavirin 
    High cost drug excluded to tariff commissioned by NHSE

    Supported in line with NICE TA 75, 106, 200
    05.05 Anthelmintics
    Mebendazole 
     ....